AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31298720 — intervention group
Group type: COMPARATOR
Intervention: Mixed group
Number of subjects: 80
Study 27056697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion protocol (70° of knee flexion)
Number of subjects: 85
Study 27056697 — intervention group
Group type: COMPARATOR
Intervention: Mild-flexion protocol (30° of knee flexion)
Number of subjects: 85
Study 26280534 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (60 mg)
Number of subjects: 1500
Study 26280534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 25102458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐fabricated primary zirconia crowns
Number of subjects: 39
Study 25102458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐veneered stainless steel crowns (SSCs)
Number of subjects: 39
Study 25102458 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite strip crowns
Number of subjects: 39
Study 23139692 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 or 6 mg based on weight) combined with Ritalin (1mg/kg)
Number of subjects: 50
Study 23139692 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with Ritalin (1mg/kg)
Number of subjects: 50
Study 19862405 — intervention group
Group type: EXPERIMENTAL
Intervention: Sof-Lex Pop-on disks (3M ESPE)
Number of subjects: 36
Study 19862405 — intervention group
Group type: COMPARATOR
Intervention: Astropol and Astrobrush system (Ivoclar Vivadent)
Number of subjects: 36
Study 17523910 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day for 4 weeks (group C)
Number of subjects: 73
Study 17523910 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day for 4 weeks (group D)
Number of subjects: 73
Study 17523910 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (group D)
Number of subjects: 73
Study 15930063 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101
Study 15930063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 12912782 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized weight and fitness health report card (PI)
Number of subjects: 1396
Study 12912782 — intervention group
Group type: EXPERIMENTAL
Intervention: General-information intervention (GI)
Number of subjects: 1396
Study 12912782 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 1396
Study 10583314 — intervention group
Group type: EXPERIMENTAL
Intervention: Washing of testosterone pellets
Number of subjects: 251
Study 10583314 — intervention group
Group type: COMPARATOR
Intervention: Control group (no washing)
Number of subjects: 251
Study 8911190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy
Number of subjects: 401
Study 8911190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy (7.5 pulses-per-second mode)
Number of subjects: 401
Study 8911190 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy
Number of subjects: 401
Study 8911190 — intervention group
Group type: COMPARATOR
Intervention: Pulsed fluoroscopy control group
Number of subjects: 401
Study 8911190 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy control group
Number of subjects: 401
Study 1905949 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms EE
Number of subjects: 6
Study 1905949 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms EE with 250 micrograms levonorgestrel (LNG)
Number of subjects: 6
Study 1905949 — intervention group
Group type: COMPARATOR
Intervention: 250 micrograms levonorgestrel (LNG) alone
Number of subjects: 6
Study 1905949 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms levonorgestrel (LNG) with 50 micrograms EE
Number of subjects: 6
Study 6342353 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin 20 mg/day
Number of subjects: 23
Study 6342353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31755292 — intervention group
Group type: EXPERIMENTAL
Intervention: collagen 4 ml
Number of subjects: 0
Study 31755292 — intervention group
Group type: COMPARATOR
Intervention: trimecaine 1% 4 ml
Number of subjects: 0
Study 29735869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic diclofenac potassium (DP) regimen (50 mg, twice daily)
Number of subjects: 41
Study 29735869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 27043165 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3026
Study 27043165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 3026
Study 27043165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3026
Study 25457123 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment (PST) - six 1-hour sessions
Number of subjects: 37
Study 25457123 — intervention group
Group type: COMPARATOR
Intervention: Social contact comparison (6 'friendly' visits)
Number of subjects: 37
Study 23284689 — intervention group
Group type: EXPERIMENTAL
Intervention: SRT2104 (0.5 or 2.0 g)
Number of subjects: 0
Study 23284689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20559637 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatectomy with Pringle maneuver (HPC group)
Number of subjects: 80
Study 20559637 — intervention group
Group type: COMPARATOR
Intervention: Hepatectomy without Pringle maneuver (NHPC group)
Number of subjects: 80
Study 17562226 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain based dietary product (WG)
Number of subjects: 31
Study 17562226 — intervention group
Group type: COMPARATOR
Intervention: Nutrient-dense meal replacement product (MR)
Number of subjects: 31
Study 15707388 — intervention group
Group type: EXPERIMENTAL
Intervention: CC carriers
Number of subjects: 715
Study 15707388 — intervention group
Group type: COMPARATOR
Intervention: AA carriers
Number of subjects: 715
Study 12072722 — intervention group
Group type: EXPERIMENTAL
Intervention: Desonide 0.25% ophthalmic solution
Number of subjects: 108
Study 12072722 — intervention group
Group type: COMPARATOR
Intervention: Fluorometholone
Number of subjects: 108
Study 9491286 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 600 mg dose of intravenous iron dextran (Imferon)
Number of subjects: 43
Study 9491286 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided doses of 100 mg intravenous iron dextran administered on 6 successive dialyses
Number of subjects: 43
Study 9491286 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly doses of intravenous iron dextran for 6 weeks
Number of subjects: 43
Study 9491286 — intervention group
Group type: COMPARATOR
Intervention: All groups (I, II, III)
Number of subjects: 43
Study 8559906 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial evaluations (30 students)
Number of subjects: 60
Study 8559906 — intervention group
Group type: COMPARATOR
Intervention: Reevaluations (30 students)
Number of subjects: 60
Study 8559906 — intervention group
Group type: COMPARATOR
Intervention: Homeroom teachers (60 teachers)
Number of subjects: 60
Study 8559906 — intervention group
Group type: COMPARATOR
Intervention: Elementary and secondary school placement
Number of subjects: 60
Study 2226542 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (alteplase) initiated early
Number of subjects: 0
Study 2226542 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy (alteplase)
Number of subjects: 0
Study 847785 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulated bed rest for three weeks
Number of subjects: 187
Study 31884683 — intervention group
Group type: EXPERIMENTAL
Intervention: MIX (menthol swilling with crushed ice ingestion)
Number of subjects: 12
Study 31884683 — intervention group
Group type: EXPERIMENTAL
Intervention: MENTH (menthol swilling with water ingestion)
Number of subjects: 12
Study 31884683 — intervention group
Group type: COMPARATOR
Intervention: CON (control)
Number of subjects: 12
Study 30081860 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility during learning (experimental block of trials in different postures: seated, standing, or free)
Number of subjects: 48
Study 30081860 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 48
Study 27222511 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol levels
Number of subjects: 1829
Study 27222511 — intervention group
Group type: COMPARATOR
Intervention: LDL cholesterol levels between 2.0 and 2.5 mmol/L
Number of subjects: 1829
Study 27222511 — intervention group
Group type: COMPARATOR
Intervention: LDL cholesterol levels >2.5 mmol/L
Number of subjects: 1829
Study 24083887 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation group intervention combined with routine care
Number of subjects: 60
Study 24083887 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study 22431901 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 17802
Study 22431901 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17802
Study 20530644 — intervention group
Group type: EXPERIMENTAL
Intervention: Modelling instructional technique
Number of subjects: 16
Study 20530644 — intervention group
Group type: COMPARATOR
Intervention: Moulding instructional technique
Number of subjects: 16
Study 18672983 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed connective tissue group (E group)
Number of subjects: 20
Study 18672983 — intervention group
Group type: COMPARATOR
Intervention: Fully covered connective tissue group (FC group)
Number of subjects: 20
Study 15982991 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5mg/kg p.o. MDMA
Number of subjects: 42
Study 15982991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 14632771 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytosine arabinoside (1 g/m2/2 h) b.i.d. for 4 days with idarubicin (CCI)
Number of subjects: 63
Study 14632771 — intervention group
Group type: COMPARATOR
Intervention: Two-drug therapy (not specified in detail)
Number of subjects: 63
Study 14632771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 63
Study 10562581 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy screening examination
Number of subjects: 241
Study 8912148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.3 U/min)
Number of subjects: 15
Study 8912148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1679065 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide 1 mg/kg/day
Number of subjects: 0
Study 1679065 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide 2 mg/kg/day
Number of subjects: 0
Study 1679065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7101824 — intervention group
Group type: EXPERIMENTAL
Intervention: cytoxan chemotherapy plus surgery plus polychemotherapy (25 patients)
Number of subjects: 75
Study 7101824 — intervention group
Group type: COMPARATOR
Intervention: surgery plus polychemotherapy (29 patients)
Number of subjects: 75
Study 7101824 — intervention group
Group type: COMPARATOR
Intervention: surgery plus polychemotherapy (21 patients with non-ascitic carcinoma)
Number of subjects: 75
Study 31995682 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement (TAVR)
Number of subjects: 2032
Study 31995682 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 2032
Study 31995682 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral access TAVR
Number of subjects: 2032
Study 31995682 — intervention group
Group type: COMPARATOR
Intervention: Surgical replacement (transfemoral access)
Number of subjects: 2032
Study 31995682 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic access TAVR
Number of subjects: 2032
Study 31995682 — intervention group
Group type: COMPARATOR
Intervention: Surgical replacement (transthoracic access)
Number of subjects: 2032
Study 31995682 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2032
Study 31995682 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 2032
Study 31995682 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR and Surgery
Number of subjects: 2032
Study 31320747 — intervention group
Group type: COMPARATOR
Intervention: singleton exome sequencing (sES)
Number of subjects: 30
Study 31320747 — intervention group
Group type: EXPERIMENTAL
Intervention: trio exome sequencing (tES)
Number of subjects: 30
Study 31320747 — intervention group
Group type: COMPARATOR
Intervention: reflexing to tES after sES
Number of subjects: 30
Study 29894978 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow flexed (EF) crutch setup
Number of subjects: 30
Study 29894978 — intervention group
Group type: COMPARATOR
Intervention: Elbow extended (EE) crutch setup
Number of subjects: 30
Study 27502807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand and foot massage
Number of subjects: 156
Study 27502807 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 156
Study 27502807 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 24831445 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS203 (20 mg/kg for 48 hours)
Number of subjects: 32
Study 24831445 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS203 (30 mg/kg for 72 hours)
Number of subjects: 32
Study 24831445 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS203
Number of subjects: 32
Study 24831445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22371549 — intervention group
Group type: EXPERIMENTAL
Intervention: Targon PF intramedullary nail
Number of subjects: 598
Study 22371549 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 598
Study 19718561 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH 75 IU with rFSH 225 IU
Number of subjects: 80
Study 19718561 — intervention group
Group type: COMPARATOR
Intervention: rFSH 225 IU only
Number of subjects: 80
Study 18299927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker continuously 'on' for three weeks followed by three weeks with the pacemaker 'off' during the night (Group A)
Number of subjects: 20
Study 18299927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker 'off' during the night for three weeks followed by pacemaker continuously 'on' for three weeks (Group B)
Number of subjects: 20
Study 18299927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker 'off' during the night
Number of subjects: 20
Study 15994627 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine spray
Number of subjects: 88
Study 15994627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 12910531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBI) - 4 sessions
Number of subjects: 48
Study 12910531 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study 12910531 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBI)
Number of subjects: 48
Study 10996354 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with primary hypertriglyceridemia and low HDL-C levels
Number of subjects: 0
Study 10996354 — intervention group
Group type: COMPARATOR
Intervention: Normotriglyceridemic subjects
Number of subjects: 0
Study 10996354 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemic patients
Number of subjects: 0
Study 9380807 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg once daily)
Number of subjects: 21
Study 9380807 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 or 40 mg twice daily)
Number of subjects: 21
Study 9380807 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 21
Study 8151105 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha interferon 2b (rIFN‐alpha 2b) 15 million units, 3 times a week for 4 months
Number of subjects: 39
Study 8151105 — intervention group
Group type: COMPARATOR
Intervention: Recombinant alpha interferon 2b (rIFN‐alpha 2b) 15 million units, 3 times a week for 4 months plus 150 mg of levamisole for the first 6 weeks
Number of subjects: 39
Study 8151105 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha interferon 2b (rIFN‐alpha 2b)
Number of subjects: 39
Study 8151105 — intervention group
Group type: COMPARATOR
Intervention: Recombinant alpha interferon 2b (rIFN‐alpha 2b) plus levamisole
Number of subjects: 39
Study 3731535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol content beer (64 ml/week)
Number of subjects: 44
Study 3731535 — intervention group
Group type: COMPARATOR
Intervention: Normal drinking habits (452 ml ethanol/week)
Number of subjects: 44
Study 30307993 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-Child Care (WCC)
Number of subjects: 71
Study 30307993 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of visit
Number of subjects: 71
Study 30307993 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal conversations with parents
Number of subjects: 71
Study 30307993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of systematic use of developmental screening measures
Number of subjects: 71
Study 30307993 — intervention group
Group type: EXPERIMENTAL
Intervention: Funding and practice nurse support to GPs
Number of subjects: 71
Study 30307993 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured WCC activities with immunisation visits
Number of subjects: 71
Study 28811096 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic (0.5% proxymetacaine)
Number of subjects: 47
Study 28811096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 47
Study 26307558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent boluses
Number of subjects: 40
Study 26307558 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 40
Study 23164997 — intervention group
Group type: EXPERIMENTAL
Intervention: PGA sheet and fibrin glue spray
Number of subjects: 44
Study 23164997 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 44
Study 21252701 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan 80 mg
Number of subjects: 405
Study 21252701 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS 20 mg
Number of subjects: 405
Study 21252701 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Telmisartan 80 mg and Nifedipine GITS 20 mg
Number of subjects: 405
Study 18719680 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD)
Number of subjects: 186
Study 18719680 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial Program
Number of subjects: 186
Study 18719680 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Guided Approach
Number of subjects: 186
Study 18719680 — intervention group
Group type: COMPARATOR
Intervention: Newsletter Control
Number of subjects: 186
Study 17315536 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg irbesartan
Number of subjects: 36
Study 17315536 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg irbesartan
Number of subjects: 36
Study 12955680 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration (HDF)
Number of subjects: 81
Study 12955680 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (HD)
Number of subjects: 81
Study 12955680 — intervention group
Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 81
Study 10877006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 30 mg
Number of subjects: 10
Study 10877006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg
Number of subjects: 10
Study 10877006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 10
Study 10877006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9174309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.8 microg/kg)
Number of subjects: 22
Study 9174309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (4.5 microg/kg)
Number of subjects: 22
Study 9174309 — intervention group
Group type: COMPARATOR
Intervention: Control (standardized anesthetic regimen)
Number of subjects: 22
Study 7515730 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMB regimen (cisplatin 50 mg/m2 day 1, vindesin 3 mg/m2 day 1, mitomycin 6 mg/m2 day 2, bleomycin 15 mg/day, day 1 + 2 by continuous infusion)
Number of subjects: 35
Study 7515730 — intervention group
Group type: EXPERIMENTAL
Intervention: CEMB regimen
Number of subjects: 35
Study 31923551 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC + CBX (200 mg twice daily)
Number of subjects: 47
Study 31923551 — intervention group
Group type: COMPARATOR
Intervention: ESC + PBO
Number of subjects: 47
Study 31923551 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IL-1β
Number of subjects: 47
Study 31082494 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib in combination with postoperative radiation therapy (PORT)
Number of subjects: 27
Study 31082494 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib in combination with PORT and weekly docetaxel
Number of subjects: 27
Study 31082494 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib in combination with PORT
Number of subjects: 27
Study 30650497 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Dachengqi Decoction (500 mL) once a day for 2 weeks
Number of subjects: 70
Study 30650497 — intervention group
Group type: COMPARATOR
Intervention: Control group (ileostomy alone)
Number of subjects: 70
Study 26434024 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES (N = 7)
Number of subjects: 15
Study 26434024 — intervention group
Group type: COMPARATOR
Intervention: RT (N = 8)
Number of subjects: 15
Study 24292746 — intervention group
Group type: EXPERIMENTAL
Intervention: Herring diet (5 meals a week for 6 weeks)
Number of subjects: 32
Study 24292746 — intervention group
Group type: COMPARATOR
Intervention: Reference meat diet
Number of subjects: 32
Study 23094808 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise program for six months
Number of subjects: 68
Study 23094808 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 68